Holen Sie sich die Stockscreener-App
21.20
1.34%
0.28
Vorhandelsmarkt:
21.15
-0.05
-0.24%
Schlusskurs vom Vortag:
$20.92
Offen:
$20.98
24-Stunden-Volumen:
1.78M
Relative Volume:
0.67
Marktkapitalisierung:
$2.68B
Einnahmen:
$631.73M
Nettoeinkommen (Verlust:
$-239.78M
KGV:
-10.50
EPS:
-2.02
Netto-Cashflow:
$-33.45M
1W Leistung:
+9.90%
1M Leistung:
+34.52%
6M Leistung:
+73.49%
1J Leistung:
+41.52%
1-Tages-Spanne:
$20.01
$21.50
1-Wochen-Bereich:
$18.41
$21.50
52-Wochen-Spanne:
$6.78
$21.50
10 X Genomics Inc Stock (TXG) Company Profile
Firmenname
10 X Genomics Inc
Sektor
Branche
Telefon
(925) 401-7300
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Vergleichen Sie TXG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
21.20 | 2.65B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
218.95 | 35.98B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
68.92 | 12.33B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
41.05 | 7.58B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
86.94 | 7.31B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
39.60 | 6.93B | 11.99B | 24.18M | 234.31M | 0.2956 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | Eingeleitet | Piper Sandler | Neutral |
| 2025-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-07-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-05-01 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-10 | Eingeleitet | Barclays | Overweight |
| 2023-03-31 | Eingeleitet | Stephens | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-08-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-07-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-14 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-02 | Eingeleitet | Goldman | Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-10 | Eingeleitet | Stifel | Buy |
| 2020-03-05 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-07 | Eingeleitet | BofA/Merrill | Buy |
| 2019-10-07 | Eingeleitet | Cowen | Outperform |
| 2019-10-07 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-24 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
Sumitomo Mitsui Trust Group Inc. Sells 636,744 Shares of 10x Genomics $TXG - MarketBeat
Aug Weekly: Whats the fair value of AN2 Therapeutics Inc stockWeekly Investment Summary & Technical Pattern Alert System - baoquankhu1.vn
Wall Street Recap: What is INTA s revenue forecastTrade Performance Summary & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Insider Trends: Will 10x Genomics Inc outperform its industry peersJuly 2025 Review & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Weak Instrument Sales And No 2026 Outlook Could Be A Game Changer For 10x Genomics (TXG) - Yahoo Finance
10x Genomics, Inc. (TXG) Stock Analysis: A Closer Look at Valuation Challenges Amidst Sector Potential - DirectorsTalk Interviews
10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling - BioSpace
Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and 10x Genomics (TXG) - The Globe and Mail
Why 10x Genomics (TXG) Shares Are Falling Today - Finviz
10x Genomics (NASDAQ:TXG) Shares Down 8.5%What's Next? - MarketBeat
10x Genomics partners with Dana-Farber to research cancer treatment responses - Investing.com
10x Genomics partners with Brigham & Women’s for autoimmune research - Investing.com
10x Genomics partners with Brigham & Women’s for autoimmune research By Investing.com - Investing.com Canada
10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease - Chartmill
Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology - PR Newswire
10x Genomics (TXG) Sees Modest Q4 Growth Amid Revenue Challenges - GuruFocus
10x Genomics sees uptick in Q4 revenue despite softer FY sales (TXG:NASDAQ) - Seeking Alpha
10x Genomics (TXG) Achieves Remarkable Progress Despite Economic Challenges - GuruFocus
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results - The Malaysian Reserve
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results | TXG Stock News - Longbridge
Revenues Not Telling The Story For 10x Genomics, Inc. (NASDAQ:TXG) After Shares Rise 32% - 富途牛牛
Cathie Wood's ARK buys Qualcomm and 10X Genomics stock - MSN
Aug Swings: Is 10x Genomics Inc. stock oversold or undervalued2025 Risk Factors & Expert Approved Momentum Trade Ideas - Улправда
Will 10x Genomics Inc. stock split attract more investorsJuly 2025 Highlights & Verified Swing Trading Watchlist - Улправда
10x Genomics (NASDAQ:TXG) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Published on: 2026-01-10 18:33:58 - moha.gov.vn
10x Genomics (NASDAQ:TXG) Reaches New 12-Month HighShould You Buy? - MarketBeat
10X Genomics stock hits 52-week high at 20.36 USD - Investing.com
10X Genomics stock hits 52-week high at 20.36 USD By Investing.com - Investing.com India
Is 10x Genomics Inc. stock a safe haven asset2025 Market Sentiment & Safe Capital Allocation Plans - ulpravda.ru
Can 10x Genomics Inc. (1KJ) stock sustain breakout momentumWeekly Gains Summary & Reliable Entry Point Alerts - Улправда
What technical charts say about 10x Genomics Inc. stockJuly 2025 Catalysts & Accurate Intraday Trade Tips - ulpravda.ru
Is 10x Genomics Inc. stock oversold or undervalued2025 Risk Factors & Expert Approved Momentum Trade Ideas - Улправда
Gains Recap: Why 10x Genomics Inc. stock is favored by top institutionsJuly 2025 Action & Free Fast Entry Momentum Trade Alerts - Улправда
Risk Check: How 10x Genomics Inc. stock benefits from strong dollar2025 Market Trends & Accurate Intraday Trading Signals - ulpravda.ru
Is 10x Genomics Inc. stock safe for conservative investorsValue Stock Picks & Free Wealth Planning Blueprints - Улправда
10x Genomics (TXG) Sees Target Price Increase in Latest Analyst Rating | TXG Stock News - GuruFocus
Why 10x Genomics Inc. stock could outperform in 2025Dividend Aristocrats List & Small Capital Trading Growth - ulpravda.ru
10x Genomics (NASDAQ:TXG) Stock Price Expected to Rise, TD Cowen Analyst Says - MarketBeat
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response - BioSpace
CareDx, 10x Genomics Establish Multiomics Research Initiative - Contract Pharma
CareDx and 10x Genomics partner on transplant rejection research - Investing.com
CareDx, Inc. and 10x Genomics to Launch ImmuneScapeA Multiomics Research Platform to Decode Transplant Rejection and Drug Response - marketscreener.com
Oklahoma City NewsThe Oklahoman - FinancialContent
10x Genomics (TXG) Stock Is Up, What You Need To Know - Finviz
10x Genomics (TXG) Gains as Analysts Raise Price Targets in Early 2026News and Statistics - IndexBox
Financial Consulate Inc. Acquires New Holdings in 10x Genomics $TXG - MarketBeat
Weekly Earnings: Is 10x Genomics Inc 1KJ stock a top pick for value investorsWeekly Investment Report & Low Drawdown Trading Strategies - moha.gov.vn
S P Trends: How dovish Fed policy supports 10x Genomics Inc 1KJ stockMarket Sentiment Review & Weekly Watchlist of Top Performers - moha.gov.vn
10x Genomics, Inc. (TXG) Stock Analysis: Navigating a Complex Market with a 7.47% Potential Upside - DirectorsTalk Interviews
10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GuruFocus
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Umsatz
Nettogewinn
Free Cashflow
ENV
10 X Genomics Inc-Aktie (TXG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Taich Adam | Chief Financial Officer |
Nov 24 '25 |
Sale |
19.00 |
11,888 |
225,852 |
297,385 |
| Hindson Benjamin J. | See Remarks |
Nov 24 '25 |
Sale |
19.00 |
8,283 |
157,363 |
432,605 |
| Saxonov Serge | Chief Executive Officer |
Nov 24 '25 |
Sale |
19.00 |
13,261 |
251,936 |
1,021,556 |
4.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):